Insight Molecular Diagnostics (IMDX) Free Cash Flow (2015 - 2026)

Insight Molecular Diagnostics has disclosed Free Cash Flow across 12 years of filings, most recently posting -$8.3 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$8.3 million, down 34.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$27.5 million (down 16.93% YoY), and the FY2025 annual result was -$25.4 million, down 19.64% from the prior year.
• Free Cash Flow came in at -$8.3 million for Q1 2026 at Insight Molecular Diagnostics, down from -$7.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$3.2 million in Q3 2023 to a low of -$14.8 million in Q1 2022.
• The 5-year median for Free Cash Flow is -$6.6 million (2025), against an average of -$7.5 million.
• Across the five-year window, Free Cash Flow jumped 73.85% in 2023 and sank 75.26% in 2024, its largest moves.
• Insight Molecular Diagnostics' Free Cash Flow stood at -$10.4 million in 2022, then surged by 55.14% to -$4.7 million in 2023, then dropped by 18.71% to -$5.6 million in 2024, then fell by 26.22% to -$7.0 million in 2025, then fell by 17.48% to -$8.3 million in 2026.
• The last three Free Cash Flow figures came in at -$8.3 million (Q1 2026), -$7.0 million (Q4 2025), and -$5.6 million (Q3 2025), per Business Quant data.